Prostaglandin E2 (PGE2)-induced growth hormone (GH) release: Effect of intrahypothalamic and intrapituitary implants

Sergio Ojeda, H. E. Jameson, S. M. McCann

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Overiectomized rats were unilaterally implanted with a 23-gauge stainless steel cannula in different hypothalamic areas or in the pituitary gland and subsequently were treated with estrogen (sc, 10 μg estradiol benzoate, Eb). Two days after the estrogen injection, an inner cannula containing PGE2 or PHF at its tip was inserted into the cannula. Other animals were implanted with empty inner cannula. Plasma GH concentrations were measured by RIA in blood samples drawn from the jugular vein while the animals were lightly etherized before (-2) and at 20, 40, 60 and 120 min following the implantation. Plasma GH levels in control animals bearing an empty cannula in the body of the arcuate nucleus-median eminence region (BARH-ME) were signifantly depressed by the ether stress. The implantation of PGF in this area was completely ineffective in preventing ether stress-induced decline in plasma GH. By contrast, PGE2 implanted in BARH-ME or the post-chiasmatic region of the hypothalamus (HARH-ME) elevated plasma GH 20 min following its implantation and partially prevented the subsequent decrease in GH levels induced by ether stress. PGE2 implants located in several other hypothalamic areas failed to induce GH release or to prevent the decline in GH levels induced by ether stress. However, PGE2 implanted in the pituitary gland elicited a marked increase in plasma GH at 20 min and completely prevented the subsequent ether stress-induced decline in GH levels. The results suggest that PGE2 can act at both hypothalamic (ARH-ME) and pituitary levels to stimulate GH release. At the hypothalamus, PGE2 may inhibit GH-inhibiting factor (GIF) release or induce release of GH releasing factor (GHRF).

Original languageEnglish (US)
Pages (from-to)943-955
Number of pages13
JournalProstaglandins
Volume13
Issue number5
DOIs
StatePublished - 1977
Externally publishedYes

Fingerprint

Dinoprostone
Growth Hormone
Ether
Plasmas
Animals
Pituitary Gland
Hypothalamus
Estrogens
Bearings (structural)
Growth Hormone-Releasing Hormone
Median Eminence
Arcuate Nucleus of Hypothalamus
Dinoprost
Stainless Steel
Jugular Veins
Gages
Rats
Blood
Cannula
Injections

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Prostaglandin E2 (PGE2)-induced growth hormone (GH) release : Effect of intrahypothalamic and intrapituitary implants. / Ojeda, Sergio; Jameson, H. E.; McCann, S. M.

In: Prostaglandins, Vol. 13, No. 5, 1977, p. 943-955.

Research output: Contribution to journalArticle

@article{105287c6b83b4b9d95af1518b2b345f5,
title = "Prostaglandin E2 (PGE2)-induced growth hormone (GH) release: Effect of intrahypothalamic and intrapituitary implants",
abstract = "Overiectomized rats were unilaterally implanted with a 23-gauge stainless steel cannula in different hypothalamic areas or in the pituitary gland and subsequently were treated with estrogen (sc, 10 μg estradiol benzoate, Eb). Two days after the estrogen injection, an inner cannula containing PGE2 or PHF2α at its tip was inserted into the cannula. Other animals were implanted with empty inner cannula. Plasma GH concentrations were measured by RIA in blood samples drawn from the jugular vein while the animals were lightly etherized before (-2) and at 20, 40, 60 and 120 min following the implantation. Plasma GH levels in control animals bearing an empty cannula in the body of the arcuate nucleus-median eminence region (BARH-ME) were signifantly depressed by the ether stress. The implantation of PGF2α in this area was completely ineffective in preventing ether stress-induced decline in plasma GH. By contrast, PGE2 implanted in BARH-ME or the post-chiasmatic region of the hypothalamus (HARH-ME) elevated plasma GH 20 min following its implantation and partially prevented the subsequent decrease in GH levels induced by ether stress. PGE2 implants located in several other hypothalamic areas failed to induce GH release or to prevent the decline in GH levels induced by ether stress. However, PGE2 implanted in the pituitary gland elicited a marked increase in plasma GH at 20 min and completely prevented the subsequent ether stress-induced decline in GH levels. The results suggest that PGE2 can act at both hypothalamic (ARH-ME) and pituitary levels to stimulate GH release. At the hypothalamus, PGE2 may inhibit GH-inhibiting factor (GIF) release or induce release of GH releasing factor (GHRF).",
author = "Sergio Ojeda and Jameson, {H. E.} and McCann, {S. M.}",
year = "1977",
doi = "10.1016/0090-6980(77)90224-6",
language = "English (US)",
volume = "13",
pages = "943--955",
journal = "Prostaglandins and Other Lipid Mediators",
issn = "1098-8823",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Prostaglandin E2 (PGE2)-induced growth hormone (GH) release

T2 - Effect of intrahypothalamic and intrapituitary implants

AU - Ojeda, Sergio

AU - Jameson, H. E.

AU - McCann, S. M.

PY - 1977

Y1 - 1977

N2 - Overiectomized rats were unilaterally implanted with a 23-gauge stainless steel cannula in different hypothalamic areas or in the pituitary gland and subsequently were treated with estrogen (sc, 10 μg estradiol benzoate, Eb). Two days after the estrogen injection, an inner cannula containing PGE2 or PHF2α at its tip was inserted into the cannula. Other animals were implanted with empty inner cannula. Plasma GH concentrations were measured by RIA in blood samples drawn from the jugular vein while the animals were lightly etherized before (-2) and at 20, 40, 60 and 120 min following the implantation. Plasma GH levels in control animals bearing an empty cannula in the body of the arcuate nucleus-median eminence region (BARH-ME) were signifantly depressed by the ether stress. The implantation of PGF2α in this area was completely ineffective in preventing ether stress-induced decline in plasma GH. By contrast, PGE2 implanted in BARH-ME or the post-chiasmatic region of the hypothalamus (HARH-ME) elevated plasma GH 20 min following its implantation and partially prevented the subsequent decrease in GH levels induced by ether stress. PGE2 implants located in several other hypothalamic areas failed to induce GH release or to prevent the decline in GH levels induced by ether stress. However, PGE2 implanted in the pituitary gland elicited a marked increase in plasma GH at 20 min and completely prevented the subsequent ether stress-induced decline in GH levels. The results suggest that PGE2 can act at both hypothalamic (ARH-ME) and pituitary levels to stimulate GH release. At the hypothalamus, PGE2 may inhibit GH-inhibiting factor (GIF) release or induce release of GH releasing factor (GHRF).

AB - Overiectomized rats were unilaterally implanted with a 23-gauge stainless steel cannula in different hypothalamic areas or in the pituitary gland and subsequently were treated with estrogen (sc, 10 μg estradiol benzoate, Eb). Two days after the estrogen injection, an inner cannula containing PGE2 or PHF2α at its tip was inserted into the cannula. Other animals were implanted with empty inner cannula. Plasma GH concentrations were measured by RIA in blood samples drawn from the jugular vein while the animals were lightly etherized before (-2) and at 20, 40, 60 and 120 min following the implantation. Plasma GH levels in control animals bearing an empty cannula in the body of the arcuate nucleus-median eminence region (BARH-ME) were signifantly depressed by the ether stress. The implantation of PGF2α in this area was completely ineffective in preventing ether stress-induced decline in plasma GH. By contrast, PGE2 implanted in BARH-ME or the post-chiasmatic region of the hypothalamus (HARH-ME) elevated plasma GH 20 min following its implantation and partially prevented the subsequent decrease in GH levels induced by ether stress. PGE2 implants located in several other hypothalamic areas failed to induce GH release or to prevent the decline in GH levels induced by ether stress. However, PGE2 implanted in the pituitary gland elicited a marked increase in plasma GH at 20 min and completely prevented the subsequent ether stress-induced decline in GH levels. The results suggest that PGE2 can act at both hypothalamic (ARH-ME) and pituitary levels to stimulate GH release. At the hypothalamus, PGE2 may inhibit GH-inhibiting factor (GIF) release or induce release of GH releasing factor (GHRF).

UR - http://www.scopus.com/inward/record.url?scp=0017625932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017625932&partnerID=8YFLogxK

U2 - 10.1016/0090-6980(77)90224-6

DO - 10.1016/0090-6980(77)90224-6

M3 - Article

C2 - 866702

AN - SCOPUS:0017625932

VL - 13

SP - 943

EP - 955

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

SN - 1098-8823

IS - 5

ER -